Posted by Michael Wonder on 24 Apr 2024
Averoa submits marketing authorisation application to the European Medicines Agency seeking approval of AVA1014 for treating complications associated with chronic kidney disease
23 April 2024 - Averoa announces the submission of a marketing authorisation application to the EMA for Ferric Citrate Coordination Complex (AVA1014), an oral iron-based compound for patients suffering from chronic kidney disease.
Ferric Citrate Coordination Complex (AVA1014) was licensed from Akebia Therapeutics in December 2022.
